|Study Participants||Healthcare Professionals||Researchers||Locations||Publications||What is TrialNet?||News and Events||Get Screened!||Home|
Information for Study Participants
CTLA-4 Ig (Abatacept) in Recent Onset Diabetes
Status: No Longer Recruiting
To join this study, you must fulfill at least one of the two conditions below:
About this Study
Type 1 diabetes is an autoimmune disease. This means that your immune system, the part of the body that helps fight infections, mistakenly attacked the cells in your body that produced insulin. These cells, called beta cells, are found in your pancreas.
This attack probably started years ago. Once many of your beta cells were damaged, your blood glucose levels went too high, and you had to start taking insulin by injection.
At this point, when you have had diabetes for less than three months, you may have beta cells left that produce some insulin. People who continue to make a little insulin may have fewer problems with low blood glucose (hypoglycemia). They may also have an easier time keeping their blood glucose levels in the normal range. This lowers the risk of the long-term complications of diabetes.
Right now, there is no proven treatment that will protect the remaining beta cells. In type 1 diabetes, the body's immune system keeps destroying them. By a few years after diagnosis, most people with type 1 diabetes are making no insulin of their own.
In this study, we are testing a drug called abatacept that might protect the remaining beta cells from further destruction. We want to see if abatacept might help people continue to make a little of their own insulin. This research study will compare people who get abatacept with those who do not get abatacept.
What will I be asked to do?
Two-thirds of the people in this study will get infusions of abatacept. They are in the treatment group.
One third of the people in this study will get infusions that look like abatacept but have no active drug. This is called a placebo infusion. The people getting the placebo infusions are in the control group.
Both groups will get 27 infusions over two years with an infusion occurring every 28 days. You will be asked to return for additional visits for up to two years after completing the infusions.
You can't choose your group. A computer will choose your group for you. It's by chance, like drawing straws. This is called random assignment, or randomization.
This study is double-masked. While the study is going on, neither you nor your study team will know if you're in the treatment group or the control group. At the end of the study, we will tell you whether you were in the treatment group or the control group.
As a research volunteer, you can decide to stop being in this study at any time. We hope that you will stay in the study. You will be helping us learn more about how to help people with diabetes.
To see if you might be eligible for this study and for a referral to a TrialNet site:
Information will be kept confidential.